

**IN THE CLAIMS**

1. (Original) A pharmaceutical composition useful for treating hematological cancer in a mammal which comprises an effective amount of an arsenic sulfide compound.
2. (Original) The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable carrier or excipient.
3. (Original) A pharmaceutical composition suitable for oral delivery to a human which comprises an effective amount of an arsenic sulfide compound.
4. (Original) The pharmaceutical composition of claim 3, further comprising a pharmaceutically acceptable carrier or excipient.
5. (Original) The pharmaceutical composition of claim 1, wherein said mammal is a human.
6. (Original) The pharmaceutical composition of claim 1, wherein the arsenic sulfide compound is selected from the group consisting of  $\text{As}_2\text{S}_2$ ,  $\text{As}_2\text{S}_3$ ,  $\text{As}_2\text{S}_5$  and  $\text{As}_4\text{S}_4$ .
7. (Original) The pharmaceutical composition of claim 6, wherein the arsenic sulfide compound is  $\text{As}_4\text{S}_4$ .
8. (Original) The pharmaceutical composition of claim 1, wherein the amount of said arsenic sulfide compound is from about 100 mg to about 2 g.
9. (Original) The pharmaceutical composition of claim 2, wherein the pharmaceutically acceptable carrier or excipient is a plant semen.
10. (Original) The pharmaceutical composition of claim 9, wherein the plant semen is *seman platycladi*.
11. (Original) The pharmaceutical composition of claim 1, further comprising an effective amount of an arsenious compound, wherein

the arsenic sulfide compound and the arsenious compound are not the same compound.

12. (Original) The pharmaceutical composition of claim 11, wherein the arsenious compound is selected from the group consisting of  $\text{As}_2\text{S}_2$ ,  $\text{As}_2\text{S}_3$ ,  $\text{As}_2\text{S}_5$ ,  $\text{As}_4\text{S}_4$  and  $\text{As}_2\text{O}_3$ .

13. (Original) The pharmaceutical composition of claim 1, further comprising an effective amount of a therapeutic agent selected from the group consisting of mustard compounds, nitrogen mustard, chlrorambucil, melphalan, cyclophosphamide busulfan, 6-mercaptopurine, 6-thioguanine, cytarabine, cytosine arabinoside, 5-fluorouracil, floxuridine, methotrexate, vincristine, vinblastine, taxol, etoposide, temiposide, dactinomycin, daunorubicin, doxorubicin, epirubicin, mitoxantron, bleomycin, mitomycin, cisplatin carboplatin, estramustine phosphate, hydroxyurea, BCNU, procarbazine, VM-26 (vumon), interferons and all-trans retinoic acid.

14. (Original) A pharmaceutical composition useful for treating hematological cancer in a mammal which comprises an effective amount of realgar and a pharmaceutically acceptable carrier or excipient.

15.-55. (Canceled)

56. (New) The pharmaceutical composition according to claim 1, wherein said pharmaceutical composition contains less than 0.15% arsenic trioxide.

57. (New) The pharmaceutical composition according to claim 1, wherein said pharmaceutical composition contains less than 0.1% arsenic trioxide.